

BIOGRAPHICAL SKETCH

| | |
|--|--|
| NAME Kang, Keon Wook | POSITION TITLE Professor, Department of Nuclear Medicine |
| eRA COMMONS USER NAME (credential, e.g., agency login) kangkw | |

| EDUCATION/TRAINING | | | |
|--|----------------------------------|-------|------------------|
| INSTITUTION AND LOCATION | DEGREE <i>(if applicable)</i> | MM/YY | FIELD OF STUDY |
| Seoul National University, Republic of Korea | M.D. | 02/91 | Medicine |
| Seoul National University, Republic of Korea | Ph.D. | 02/01 | Nuclear Medicine |

A. Personal Statement

Dr. Keon W. Kang, a nuclear medicine physician, is a professor and the Chairman of the Department of Nuclear Medicine, Seoul National University College of Medicine. He received an M.D. degree from Seoul National University College of Medicine (1991). He was trained as an intern and a resident for Internal Medicine at Seoul National University Hospital (1991-1996). He received Ph.D. in Medical Science at Seoul National University College of Medicine (2001). He has worked as Chief, Department of Nuclear Medicine, National Cancer Center, Korea (2000-2007). He studied molecular imaging and researched “Preclinical efficacy of the c-Met Inhibitor from Pfizer Inc. by small-animal PET” with Pf. Sam Gambhir as a visiting scientist of Molecular Imaging Program at Stanford (2003-2004). His research areas are in vivo molecular imaging of cancer using PET & nanoparticles.

B. Positions and Honors

Positions and Employment

1991-1996 Intern-Residency, Department of Internal Medicine, Seoul National University Hospital, Korea
 1999-2000 Fellowship, Department of Nuclear Medicine, Seoul National University Hospital, Korea
 2000-2006 Chief, Department of Nuclear Medicine, Hospital, National Cancer Center, Korea
 2000-2002 Team Leader, Information Technology Team, National Cancer Center, Korea
 2002-2006 Chief, Cancer Information Branch, National Cancer Center, Korea
 2003-2004 Visiting Scientist, Molecular Imaging Program at Stanford University, Stanford, CA
 2007-2012 Associate Professor, Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
 2007- Executive Vice Director, Cancer Research Institute, Seoul National University, Seoul, Korea
 2012- Professor, Department of Nuclear Medicine, Seoul National University College of Medicine
 2012-2016 Radiation Safety Officer, Seoul National University Hospital
 2013-2019 Director, Yongon Center, Office of Information Systems and Technology, Seoul National University
 2014-2019 Chairman, Department of Nuclear Medicine, Seoul National University Hospital
 2015-2019 Chairman, Department of Nuclear Medicine, Seoul National University College of Medicine
 2019- Vice Director, Bio-MAX Institute, Seoul National University, Seoul, Korea

Other Experience and Professional Memberships

1996- Lifetime Member, the Korean Association of Internal Medicine
 1997- Board Member, the Korean Society of Nuclear Medicine
 2000- Member, the Society of Nuclear Medicine and Molecular Imaging

- 2002- Member, the Academy of Molecular Imaging
- 2002- Board Member, the Korean Society of Molecular Imaging
- 2003- Lifetime Member, the Korean Cancer Association
- 2003- Member, the Society for Molecular Imaging
- 2005- Member, the European Association of Nuclear Medicine
- 2005-2006 Oncology PET Track Coordinator, 9th World Congress of Nuclear Medicine and Biology
- 2006- Member, Federation of Asian Societies for Molecular Imaging
- 2009- Member, the European Society for Nanomedicine
- 2009- Lifetime Member, the American Society for Nanomedicine
- 2011- Editorial Board Member, Nanomedicine (ISSN 1743-5889)
- 2011- Editorial Board Member, American J Nuclear Medicine and Molecular Imaging (ISSN 2160-8407)
- 2011- Board Member, Korean Association for Radiation Protection
- 2012-2018 Board Member, Korea Foundation of Nuclear Safety
- 2012-2014 Member, Steering Committee & Program Committee, World Molecular Imaging Society
- 2013- Member, Committee 3 (Medicine), International Commission on Radiological Protection
- 2013- Editorial Board Member, Current Medical Imaging Reviews (ISSN 1573-4056)
- 2013- Editorial Board Member, Asia Oceania Journal of Nuclear Medicine & Biology (ISSN 2322-5718)
- 2017-2019 President, the Korean Society for Nanomedicine

Honors

- 1995 Distinguished Young Investigator's Award from Asia and Oceania, the Japan Society of Nuclear Medicine, Yokohama, Japan
- 1999 The Best Poster Award, the Korean Society of Nuclear Medicine, Korea
- 2000 Travel Award, the Organization for Human Brain Mapping, San Antonio, TX
- 2001 Ministerial Citation, Ministry of Health & Welfare, Korea
- 2002 The Korean Federation of Science and Technology Societies Award, Korea
- 2016 Ministerial Citation, Ministry of Science, ICT and Future Planning, Korea

C. List of Publications

Peer-reviewed Publications

1. Kang YK, Choi JY, Paeng JC, Kim YI, Kwon HW, Cheon GJ, Suh KS, Kwon CHD, Lee DS, Kang KW. Composite criteria using clinical and FDG PET/CT factors for predicting recurrence of hepatocellular carcinoma after living donor liver transplantation. *Eur Radiol.* 2019 May 21. [Epub ahead of print]
2. Shagera QA, Cheon GJ, Koh Y, Yoo MY, Kang KW, Lee DS, Kim EE, Yoon SS, Chung JK. Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. *Eur J Nucl Med Mol Imaging.* 2019 Jul;46(7):1417-1427.
3. Jang JT, Lee J, Seon J, Ju E, Kim M, Kim YI, Kim MG, Takemura Y, Arbab AS, Kang KW, Park KH, Paek SH, Bae S. Giant Magnetic Heat Induction of Magnesium-Doped γ -Fe₂O₃ Superparamagnetic Nanoparticles for Completely Killing Tumors. *Adv Mater.* 2019 Mar;31(12):e1806347.
4. Lodhi NA, Park JY, Kim K, Kim YJ, Shin JH, Lee YS, Im HJ, Jeong JM, Khalid M, Cheon GJ, Lee DS, Kang KW. Development of 99mTc-Labeled Human Serum Albumin with Prolonged Circulation by Chelate-then-Click Approach: A Potential Blood Pool Imaging Agent. *Mol Pharm.* 2019 Apr 1;16(4):1586-1595.
5. Song HC, Na MH, Kim J, Cho SG, Park JK, Kang KW; Korean Society of Nuclear Medicine Diagnostic Reference Level Task Force. Diagnostic Reference Levels for Adult Nuclear Medicine Imaging Established from the National Survey in Korea. *Nucl Med Mol Imaging.* 2019 Feb;53(1):64-70.
6. Kim SJW, Seo S, Kim HS, Kim DY, Kang KW, Min JJ, Lee JS. Multi-atlas cardiac PET segmentation. *Phys Med.* 2019 Feb;58:32-39.
7. Kim MJ, Lee CH, Lee Y, Youn H, Kang KW, Kwon J, Alavi A, Carlin S, Cheon GJ, Chung JK. Glucose-6-phosphatase Expression-Mediated [18F]FDG Efflux in Murine Inflammation and Cancer Models. *Mol Imaging Biol.* 2019 Feb 4. [Epub ahead of print]

8. Bakht MK, Derecichei I, Li Y, Ferraiuolo RM, Dunning MJ, Oh SW, Hussein A, Youn H, Stringer KF, Jeong CW, Cheon GJ, Kwak C, Kang KW, Lamb A, Wang Y, Dong X, Porter L. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. *Endocr Relat Cancer*. 2018 Nov 23;26(2):131-146.
9. Koh Y, Lee JM, Woo GU, Paeng JC, Youk J, Yoon SS, Kim I, Kang KW. FDG PET for Evaluation of Bone Marrow Status in T-Cell Lymphoma. *Clin Nucl Med*. 2019 Jan;44(1):4-10.
10. Kim HJ, Lee R, Choi H, Paeng JC, Cheon GJ, Lee DS, Chung JK, Kang KW. Application of Quantitative Indexes of FDG PET to Treatment Response Evaluation in Indolent Lymphoma. *Nucl Med Mol Imaging*. 2018 Oct;52(5):342-349.
11. Lee HH, Paeng JC, Cheon GJ, Lee DS, Chung JK, Kang KW. Recurrence of Melanoma After Initial Treatment: Diagnostic Performance of FDG PET in Posttreatment Surveillance. *Nucl Med Mol Imaging*. 2018 Oct;52(5):327-333.
12. Chung SJ, Youn H, Jeong EJ, Park CR, Kim MJ, Kang KW, Zhang MR, Cheon GJ. In vivo imaging of activated macrophages by 18F-FEDAC, a TSPO targeting PET ligand, in the use of biologic disease-modifying anti-rheumatic drugs (bDMARDs). *Biochem Biophys Res Commun*. 2018 Oct 18. pii: S0006-291X(18)32239-3.
13. Lee CH, Kim MJ, Lee HH, Paeng JC, Park YJ, Oh SW, Chai YJ, Kim YA, Cheon GJ, Kang KW, Youn H, Chung JK. Adenine Nucleotide Translocase 2 as an Enzyme Related to [18F] FDG Accumulation in Various Cancers. *Mol Imaging Biol*. 2018 Sep 17. [Epub ahead of print]
14. Lee R, Kim J, Paeng JC, Byun JW, Cheon GJ, Lee DS, Chung JK, Kang KW. Measurement of 68Ga-DOTATOC Uptake in the Thoracic Aorta and Its Correlation with Cardiovascular Risk. *Nucl Med Mol Imaging*. 2018 Aug;52(4):279-286.
15. Kim YI, Paeng JC, Park YS, Cheon GJ, Lee DS, Chung JK, Kang KW. Relation of EGFR Mutation Status to Metabolic Activity in Localized Lung Adenocarcinoma and Its Influence on the Use of FDG PET/CT Parameters in Prognosis. *AJR Am J Roentgenol*. 2018 Jun;210(6):1346-1351.
16. Park S, Paeng JC, Kang CH, Cheon GJ, Kang KW, Chung JK, Lee DS. Dual-time point 18F-FDG PET/CT for the staging of oesophageal cancer: the best diagnostic performance by retention index for N-staging in non-calcified lymph nodes. *Eur J Nucl Med Mol Imaging*. 2018 Jul;45(8):1317-1328.
17. Lee H, Paeng JC, Kim KH, Cheon GJ, Lee DS, Chung JK, Kang KW. Correlation of FDG PET/CT Findings with Long-Term Growth and Clinical Course of Abdominal Aortic Aneurysm. *Nucl Med Mol Imaging*. 2018 Feb;52(1):46-52.
18. Chung SJ, Yoon HJ, Youn H, Kim MJ, Lee YS, Jeong JM, Chung JK, Kang KW, Xie L, Zhang MR, Cheon GJ. 18F-FEDAC as a Targeting Agent for Activated Macrophages in DBA/1 Mice with Collagen-Induced Arthritis: Comparison with 18F-FDG. *J Nucl Med*. 2018 May;59(5):839-845.
19. Kim YI, Cheon GJ, Kang SY, Paeng JC, Kang KW, Lee DS, Chung JK. Prognostic value of simultaneous 18F-FDG PET/MRI using a combination of metabolo-volumetric parameters and apparent diffusion coefficient in treated head and neck cancer. *EJNMMI Res*. 2018 Jan 10;8(1):2.
20. Vano E, Miller DL, Martin CJ, Rehani MM, Kang K, Rosenstein M, Ortiz-Lopez P, Mattsson S, Padovani R, Rogers A. Diagnostic Reference Levels in Medical Imaging. ICRP Publication 135. *Ann. ICRP* 46(1), 2017
21. Jang JT, Lee J, Seon J, Ju E, Kim M, Kim YI, Kim MG, Takemura Y, Arbab AS, Kang KW, Park KH, Paek SH, Bae S. Giant Magnetic Heat Induction of Magnesium-Doped γ -Fe₂O₃ Superparamagnetic Nanoparticles for Completely Killing Tumors. *Adv Mater*. 2018 Feb;30(6).
22. Lee MS, Kim JH, Paeng JC, Kang KW, Jeong JM, Lee DS, Lee JS. Whole-body voxel-based personalized dosimetry: Multiple voxel S-value approach for heterogeneous media with non-uniform activity distributions. *J Nucl Med*. 2018 Jul;59(7):1133-1139.
23. Paek SH, Yi KH, Kim SJ, Choi JY, Lee KE, Park YJ, Park DJ, Kang KW, Chung JK. Feasibility of sentinel lymph node dissection using Tc-99m phytate in papillary thyroid carcinoma. *Ann Surg Treat Res*. 2017 Nov;93(5):240-245.
24. Lee HS, Lee S, Park S, Baek Y, Youn JH, Cho DB, Jin JH, Shin A, Park SK, Kang KW, Lim YK, Kang CH, Yoo KY, Ko KP. The association between somatic and psychological discomfort and health-related quality of life according to the elderly and non-elderly. *Qual Life Res*. 2018 Mar;27(3):673-681.

25. Bakht MK, Oh SW, Youn H, Cheon GJ, Kwak C, Kang KW. Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges. *Nucl Med Mol Imaging*. 2017 Sep;51(3):202-211.
26. Lee IJ, Park JY, Kim YI, Lee YS, Jeong JM, Kim J, Kim EE, Kang KW, Lee DS, Jeong S, Kim EJ, Kim YI, Chung JW. Image-Based Analysis of Tumor Localization After Intra-Arterial Delivery of Technetium-99m-Labeled SPIO Using SPECT/CT and MRI. *Mol Imaging*. 2017 Jan 1;16:1536012116689001.
27. Kim YI, Kim YJ, Paeng JC, Cheon GJ, Lee DS, Chung JK, Kang KW. Heterogeneity index evaluated by slope of linear regression on 18F-FDG PET/CT as a prognostic marker for predicting tumor recurrence in pancreatic ductal adenocarcinoma. *Eur J Nucl Med Mol Imaging*. 2017 Nov;44(12):1995-2003.
28. Kim YI, Kim YJ, Paeng JC, Cheon GJ, Lee DS, Chung JK, Kang KW. Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer. *Eur J Nucl Med Mol Imaging*. 2017 Oct;44(11):1787-1795.
29. Kang SY, Rahim MK, Kim YI, Cheon GJ, Kang HJ, Shin HY, Kang KW, Chung JK, Kim EE, Lee DS. Clinical Significance of Pretreatment FDG PET/CT in MIBG-Avid Pediatric Neuroblastoma. *Nucl Med Mol Imaging*. 2017 Jun;51(2):154-160.
30. Bang JI, Lim Y, Paeng JC, Han SW, Park S, Lee JM, Kim HJ, Cheon GJ, Lee DS, Chung JK, Kim TY, Kang KW. Comparison of Quantitative Methods on FDG PET/CT for Treatment Response Evaluation of Metastatic Colorectal Cancer. *Nucl Med Mol Imaging*. 2017 Jun;51(2):147-153.
31. Kim JW, Seo S, Kim HS, Kim DY, Lee HY, Kang KW, Lee DS, Bom HS, Min JJ, Lee JS. Comparative evaluation of the algorithms for parametric mapping of the novel myocardial PET imaging agent 18F-FPTP. *Ann Nucl Med*. 2017 Jul;31(6):469-479.
32. Kim YI, Jeong S, Jung KO, Song MG, Lee CH, Chung SJ, Park JY, Cha MG, Lee SG, Jun BH, Lee YS, Hwang DW, Youn H, Kang KW, Lee YS, Jeong DH, Lee DS. Simultaneous Detection of EGFR and VEGF in Colorectal Cancer using Fluorescence-Raman Endoscopy. *Sci Rep*. 2017 Apr 21;7(1):1035.
33. Kim MJ, Oh SW, Youn H, Na J, Kang KW, Park DJ, Park YJ, Jang JJ, Lee KE, Jung KC, Chung JK. Thyroid-Related Protein Expression in the Human Thymus. *Int J Endocrinol*. 2017 2017;2017:8159892.
34. Kim YI, Paeng JC, Cheon GJ, Kang KW, Lee DS, Chung JK. Discrepancy Between Tumor Antigen Distribution and Radiolabeled Antibody Binding in a Nude Mouse Xenograft Model of Human Melanoma. *Cancer Biother Radiopharm*. 2017 Apr;32(3):83-89.
35. Lee SJ, Paeng JC, Goo JM, Lee JM, Cheon GJ, Lee DS, Chung JK, Kang KW. Comparative characteristics of quantitative indexes for 18F-FDG uptake and metabolic volume in sequentially obtained PET/MRI and PET/CT. *Nucl Med Commun*. 2017 Apr;38(4):333-339.
36. Bakht MK, Oh SW, Hwang DW, Lee YS, Youn H, Porter LA, Cheon GJ, Kwak C, Lee DS, Kang KW. The potential roles of radionanomedicine and radioexosomic in prostate cancer research and treatment. *Curr Pharm Des*. 2017;23(20):2976-2990.
37. Lim YJ, Chang JH, Kim HJ, Keam B, Kim TM, Kim DW, Paeng JC, Kang KW, Chung JK, Jeon YK, Chung DH, Wu HG. Superior Treatment Response and In-field Tumor Control in Epidermal Growth Factor Receptor-mutant Genotype of Stage III Nonsquamous Non-Small cell Lung Cancer Undergoing Definitive Concurrent Chemoradiotherapy. *Clin Lung Cancer*. 2017 May;18(3):e169-e178.
38. Sim JA, Chang YJ, Shin A, Noh DY, Han W, Yang HK, Kim YW, Kim YT, Jeong SY, Yoon JH, Kim YJ, Heo D, Kim TY, Oh DY, Wu HG, Kim HJ, Chie EK, Kang KW, Kim JH, Yun YH. Perceived needs for the information communication technology (ICT)-based personalized health management program, and its association with information provision, health-related quality of life (HRQOL), and decisional conflict in cancer patients. *Psychooncology*. 2017 Nov;26(11):1810-1817.
39. Jung KO, Youn H, Lee CH, Kang KW, Chung JK. Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells. *Oncotarget*. 2017 Feb 7;8(6):9899-9910.
40. Chung T, Na J, Kim YI, Chang DY, Kim YI, Kim H, Moon HE, Kang KW, Lee DS, Chung JK, Kim SS, Suh-Kim H, Paek SH, Youn H. Dihydropyrimidine Dehydrogenase Is a Prognostic Marker for Mesenchymal Stem Cell-Mediated Cytosine Deaminase Gene and 5-Fluorocytosine Prodrug Therapy for the Treatment of Recurrent Gliomas. *Theranostics*. 2016 Jun 17;6(10):1477-90.
41. Jeong HJ, Lee BC, Ahn BC, Kang KW. Development of Drugs and Technology for Radiation Theragnosis. *Nucl Eng Technol*. 2016 Jun;48(3):597-607.

42. Park S, Cheon GJ, Paeng JC, Won KS, Kang KW, Kim KB, Chung JK, Lee DS. Phase analysis of gated myocardial perfusion single-photon emission computed tomography after coronary artery bypass graft surgery: reflection of late reverse remodeling in patients with patent grafts after coronary artery bypass graft surgery. *Nucl Med Commun.* 2016 Nov;37(11):1139-47
43. Jung KO, Youn H, Kim SH, Kim YH, Kang KW, Chung JK. A new fluorescence/PET probe for targeting intracellular human telomerase reverse transcriptase (hTERT) using Tat peptide-conjugated IgM. *Biochem Biophys Res Commun.* 2016 Aug 26;477(3):483-9.
44. Lee H, Paeng JC, Hong SH, Yoo HJ, Cheon GJ, Lee DS, Chung JK, Kang KW. Appropriate margin thresholds for isocontour metabolic volumetry of fluorine-18 fluorodeoxyglucose PET in sarcoma: a hybrid PET/MRI study. *Nucl Med Commun.* 2016 Oct;37(10):1088-94.
45. Kim YI, Yoon HJ, Paeng JC, Cheon GJ, Lee DS, Chung JK, Kim EE, Moon WK, Kang KW. Prognostic Value of 68Ga-NOTA-RGD PET/CT for Predicting Disease-Free Survival for Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy and Surgery: A Comparison Study With Dynamic Contrast Enhanced MRI. *Clin Nucl Med.* 2016 Aug;41(8):614-20.
46. Im HJ, Oo S, Jung W, Jang JY, Kim SW, Cheon GJ, Kang KW, Chung JK, Kim EE, Lee DS. Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer. *Medicine (Baltimore).* 2016 May;95(19):e3686.
47. Lee DH, Lee JM, Hur BY, Joo I, Yi NJ, Suh KS, Kang KW, Han JK. Colorectal Cancer Liver Metastases: Diagnostic Performance and Prognostic Value of PET/MR Imaging. *Radiology.* 2016 Oct;37(10):1088-94.
48. Kwon HW, Lee HY, Hwang YH, Park HC, Ahn C, Kang KW. Diagnostic performance of 18F-FDG-labeled white blood cell PET/CT for cyst infection in patients with autosomal dominant polycystic kidney disease: a prospective study. *Nucl Med Commun.* 2016 May;37(5):493-8.
49. Kim WH, Kim CG, Kim MH, Kim DW, Park CR, Park JY, Lee YS, Youn H, Kang KW, Jeong JM, Chung JK. Preclinical evaluation of isostructural Tc-99m- and Re-188-folate-Gly-Gly-Cys-Glu for folate receptor-positive tumor targeting. *Ann Nucl Med.* 2016 Jun;30(5):369-79.
50. Kim YI, Paeng JC, Cheon GJ, Suh KS, Lee DS, Chung JK, Kang KW. Prediction of Post-Transplantation Recurrence of Hepatocellular Carcinoma by Using Metabolic and Volumetric Indices of 18F-FDG PET/CT. *J Nucl Med.* 2016 Jul;57(7):1045-51.
51. Kwon HW, Kim JP, Lee HJ, Paeng JC, Lee JS, Cheon GJ, Lee DS, Chung JK, Kang KW. Radiation Dose from Whole-Body F-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: Nationwide Survey in Korea. *J Korean Med Sci.* 2016 Feb;31 Suppl 1:S69-74.
52. Kang KW. History and Organizations for Radiological Protection. *J Korean Med Sci.* 2016 Feb;31 Suppl 1:S4-5.
53. Lee SW, Kang KW, Wu HG. Prospective investigation and literature review of tolerance dose on salivary glands using quantitative salivary gland scintigraphy in the intensity-modulated radiotherapy era. *Head Neck.* 2016 Apr;38 Suppl 1:E1746-55.
54. Choi H, Cheon GJ, Kim HJ, Choi SH, Kim YI, Kang KW, Chung JK, Kim EE, Lee DS. Gray matter correlates of dopaminergic degeneration in Parkinson's disease: A hybrid PET/MR study using 18 F-FP-CIT. *Hum Brain Mapp.* 2016 May;37(5):1710-21.
55. Im HJ, Paeng JC, Cheon GJ, Kim EE, Lee JS, Goo JM, Kang KW, Chung JK, Lee DS. Feasibility of simultaneous 18F-FDG PET/MRI for the quantitative volumetric and metabolic measurements of abdominal fat tissues using fat segmentation. *Nucl Med Commun.* 2016 Jun;37(6):616-22.
56. Sarker A, Im HJ, Cheon GJ, Chung HH, Kang KW, Chung JK, Kim EE, Lee DS. Prognostic Implications of the SUVmax of Primary Tumors and Metastatic Lymph Node Measured by 18F-FDG PET in Patients With Uterine Cervical Cancer: A Meta-analysis. *Clin Nucl Med.* 2016 Jan;41(1):34-40.
57. Chung T, Youn H, Yeom CJ, Kang KW, Chung JK. Glycosylation of Sodium/Iodide Symporter (NIS) Regulates Its Membrane Translocation and Radioiodine Uptake. *PLoS One.* 2015 Nov 23;10(11):e0142984.
58. Yoo MY, Paeng JC, Cheon GJ, Lee DS, Chung JK, Kim EE, Kang KW. Prognostic Value of Metabolic Tumor Volume on (11)C-Methionine PET in Predicting Progression-Free Survival in High-Grade Glioma. *Nucl Med Mol Imaging.* 2015 Dec;49(4):291-7
59. Lee I, Paeng JC, Lee SJ, Shin CS, Jang JY, Cheon GJ, Lee DS, Chung JK, Kang KW. Comparison of Diagnostic Sensitivity and Quantitative Indices Between (68)Ga-DOTATOC PET/CT and

- (111)In-Pentetretotide SPECT/CT in Neuroendocrine Tumors: a Preliminary Report. *Nucl Med Mol Imaging*. 2015 Dec;49(4):284-90.
60. Seo HJ, Pagsisihan JR, Paeng JC, Choi SH, Cheon GJ, Chung JK, Lee DS, Kang KW. Hemodynamic Significance of Internal Carotid or Middle Cerebral Artery Stenosis Detected on Magnetic Resonance Angiography. *Yonsei Med J*. 2015 Nov;56(6):1686-93.
61. Sim JA, Shin JS, Park SM, Chang YJ, Shin A, Noh DY, Han W, Yang HK, Lee HJ, Kim YW, Kim YT, Jeong SY, Yoon JH, Kim YJ, Heo DS, Kim TY, Oh DY, Wu HG, Kim HJ, Chie EK, Kang KW, Yun YH. Association between Information Provision and Decisional Conflict in Cancer Patients. *Ann Oncol*. 2015 Sep;26(9):1974-80.
62. Song YS, Paeng JC, Kim HC, Chung JW, Cheon GJ, Chung JK, Lee DS, Kang KW. PET/CT-Based Dosimetry in 90Y-Microsphere Selective Internal Radiation Therapy: Single Cohort Comparison With Pretreatment Planning on 99mTc-MAA Imaging and Correlation With Treatment Efficacy. *Medicine (Baltimore)*. 2015 Jun;94(23):e945.
63. Cho N, Im SA, Kang KW, Park IA, Song IC, Lee KH, Kim TY, Lee H, Chun IK, Yoon HJ, Moon WK. Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography. *Eur Radiol*. 2016 Jul;26(7):2279-90.
64. Keam B, Lee SJ, Kim TM, Paeng JC, Lee SH, Kim DW, Jeon YK, Chung DH, Kang KW, Chung JK, Heo DS. Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation. *J Thorac Oncol*. 2015 Aug;10(8):1189-94.
65. Lee SJ, Seo HJ, Kang KW, Jeong SY, Yi NJ, Lee JM, Chung JK, Edmund Kim E, Paeng JC, Cheon GJ, Lee DS. Clinical Performance of Whole-Body 18F-FDG PET/Dixon-VIBE, T1-Weighted, and T2-Weighted MRI Protocol in Colorectal Cancer. *Clin Nucl Med*. 2015 Aug;40(8):e392-8. 교신
66. Koo HR, Park JS, Kang KW, Han W, Park IA, Moon WK. Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer. *Eur Radiol*. 2015 Nov;25(11):3314-21.
67. Jeong S, Kim YI, Kang H, Kim G, Cha MG, Chang H, Jung KO, Kim YH, Jun BH, Hwang do W, Lee YS, Youn H, Lee YS, Kang KW, Lee DS, Jeong DH. Fluorescence-Raman dual modal endoscopic system for multiplexed molecular diagnostics. *Sci Rep*. 2015 Mar 30;5:9455.
68. Seo HJ, Ryu YH, Lee I, Min HS, Kang KW, Lee DS, Lee DH, Chung JK. Usefulness of (131)I-SPECT/CT and (18)F-FDG PET/CT in Evaluating Successful (131)I and Retinoic Acid Combined Therapy in a Patient with Metastatic Struma Ovarii. *Nucl Med Mol Imaging*. 2015 Mar;49(1):52-6.
69. Kim YI, Cheon GJ, Paeng JC, Cho JY, Kwak C, Kang KW, Chung JK, Kim EE, Lee DS. Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization. *Eur J Nucl Med Mol Imaging*. 2015 Jul;42(8):1247-56.
70. Ha S, Hong SH, Paeng JC, Lee DY, Cheon GJ, Arya A, Chung JK, Lee DS, Kang KW. Comparison of SPECT/CT and MRI in diagnosing symptomatic lesions in ankle and foot pain patients: diagnostic performance and relation to lesion type. *PLoS One*. 2015 Feb 10;10(2):e0117583.
71. Pak K, Park S, Cheon GJ, Kang KW, Kim IJ, Lee DS, Kim EE, Chung JK. Update on nodal staging in non-small cell lung cancer with integrated positron emission tomography/computed tomography: a meta-analysis. *Ann Nucl Med*. 2015 Jun;29(5):409-19.
72. Kim YH, Youn H, Na J, Hong KJ, Kang KW, Lee DS, Chung JK. Codon-optimized Human Sodium Iodide Symporter (opt-hNIS) as a Sensitive Reporter and Efficient Therapeutic Gene. *Theranostics*. 2015 Jan 1;5(1):86-96.
73. Kong SH, Noh YW, Suh YS, Park HS, Lee HJ, Kang KW, Kim HC, Lim YT, Yang HK. Evaluation of the novel near-infrared fluorescence tracers pullulan polymer nanogel and indocyanine green/ γ -glutamic acid complex for sentinel lymph node navigation surgery in large animal models. *Gastric Cancer*. 2015 Jan;18(1):55-64.
74. Lee I, Budiawan H, Moon JY, Cheon GJ, Kim YC, Paeng JC, Kang KW, Chung JK, Lee DS. The Value of SPECT/CT in Localizing Pain Site and Prediction of Treatment Response in Patients with Chronic Low Back Pain. *J Korean Med Sci*. 2014 Dec;29(12):1711-6.
75. Oh Jung K, Youn H, Kim YH, Kim S, Na J, Kim YI, Park JW, Kang KW, Lee DS, Chung JK. Relationship between Apoptosis Imaging and Radioiodine Therapy in Tumor Cells with Different Sodium Iodide Symporter Gene Expression. *Mol Imaging*. 2014 Nov 1;13(0):1-9.

76. Pak K, Cheon GJ, Kang KW, Chung JK, Kim EE, Lee DS. Prognostic Value of SUVmean in Oropharyngeal and Hypopharyngeal Cancers: Comparison with SUVmax and Other Volumetric Parameters of 18F-FDG PET. *Clin Nucl Med*. 2015 Jan;40(1):9-13.
77. Kim YI, Im HJ, Paeng JC, Cheon GJ, Kang KW, Lee DS, Joon Park D, Park YJ, Chung JK. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer. *Ann Nucl Med*. 2015 Feb;29(2):184-9.
78. Choi H, Bang JI, Cheon GJ, Kim YH, Park CK, Park SH, Kang KW, Chung JK, Kim EE, Lee DS. 18F-Fluorodeoxyglucose and 11C-methionine positron emission tomography in relation to methyl-guanine methyltransferase promoter methylation in high-grade gliomas. *Nucl Med Commun*. 2015 Mar;36(3):211-8.
79. Lee S, Youn H, Chung T, Hwang do W, Oh SW, Kang KW, Chung JK, Lee DS. In vivo bioluminescence imaging of transplanted mesenchymal stem cells as a potential source for pancreatic regeneration. *Mol Imaging*. 2014;13:1-12.
80. Im HJ, Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, Chung JK, Kim EE, Lee DS. Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis. *Eur J Nucl Med Mol Imaging*. 2015 Feb;42(2):241-51.
81. Pak K, Suh S, Hong H, Cheon GJ, Hahn SK, Kang KW, Kim EE, Lee DS, Chung JK. Diagnostic values of thyroglobulin measurement in fine-needle aspiration of lymph nodes in patients with thyroid cancer. *Endocrine*. 2015 May;49(1):70-7.
82. Cho Y, Lee DH, Lee YB, Lee M, Yoo JJ, Choi WM, Cho YY, Paeng JC, Kang KW, Chung JK, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim YJ. Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma? *PLoS One*. 2014 Aug 25;9(8):e105679
83. Choi H, Cheon GJ, Kim HJ, Choi SH, Lee JS, Kim YI, Kang KW, Chung JK, Kim EE, Lee DS. Segmentation-Based MR Attenuation Correction Including Bones Also Affects Quantitation in Brain Study: An Initial Result of 18F-FP-CIT PET/MR for Patients with Parkinsonism. *J Nucl Med*. 2014 Oct;55(10):1617-22.
84. Khang AR, Cho SW, Choi HS, Ahn HY, Yoo WS, Kim KW, Kang KW, Yi KH, Park DJ, Lee DS, Chung JK, Cho BY, Park YJ. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative 131 I dose over 37 GBq. *Clin Endocrinol (Oxf)*. 2015 Jul;83(1):117-23.
85. Kim YI, Phi JH, Paeng JC, Choi H, Kim SK, Lee YS, Kang KW, Lee JY, Jeong JM, Chung JK, Lee DS, Wang KC. In Vivo Evaluation of Angiogenic Activity and Its Correlation with Efficacy of Indirect Revascularization Surgery in Pediatric Moyamoya Disease. *J Nucl Med*. 2014 Sep;55(9):1467-72.
86. Pak K, Cheon GJ, Nam HY, Kim SJ, Kang KW, Chung JK, Kim EE, Lee DS. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Head and Neck Cancer: A Systematic Review and Meta-Analysis. *J Nucl Med*. 2014 Apr 21;55(6):884-890.
87. Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, Kim EE, Lee DS, Chung JK. The effectiveness of recombinant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant ablation in thyroid cancer: a meta-analysis of randomized controlled trials. *J Korean Med Sci*. 2014 Jun;29(6):811-7
88. Seo HJ, Kang KW, Lee DS, Goo JM, Kim YT, Park YS, Cheon GJ. Evaluation of Azygous Vein Aneurysm Using Integrated PET/MRI. *Nucl Med Mol Imaging*. 2014 Jun;48(2):161-2
89. Lee SJ, Seo HJ, Cheon GJ, Kim JH, Kim EE, Kang KW, Paeng JC, Chung JK, Lee DS. Usefulness of Integrated PET/MRI in Head and Neck Cancer: A Preliminary Study. *Nucl Med Mol Imaging*. 2014 Jun;48(2):98-105.
90. Rahim MK, Kim SE, So H, Kim HJ, Cheon GJ, Lee ES, Kang KW, Lee DS. Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology. *Nucl Med Mol Imaging*. 2014 Mar;48(1):1-15
91. Yoon HJ, Kang KW, Chun IK, Cho N, Im SA, Jeong S, Lee S, Jung KC, Lee YS, Jeong JM, Lee DS, Chung JK, Moon WK. Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from 68Ga-RGD PET/CT and 18F-FDG PET/CT. *Eur J Nucl Med Mol Imaging*. 2014 Aug;41(8):1534-43
92. Choi H, Paeng JC, Cheon GJ, Park CK, Choi SH, Min HS, Kang KW, Chung JK, Kim EE, Lee DS. Correlation of 11C-methionine PET and diffusion-weighted MRI: is there a complementary diagnostic role for gliomas? *Nucl Med Commun*. 2014 Jul;35(7):720-6.

93. Im HJ, Lee IK, Paeng JC, Lee KE, Cheon GJ, Kang KW, Chung JK, Lee DS. Functional evaluation of parathyroid adenoma using 99mTc-MIBI parathyroid SPECT/CT: correlation with functional markers and disease severity. *Nucl Med Commun*. 2014 Jun;35(6):649-54.
94. Kim YI, Cheon GJ, Paeng JC, Cho JY, Kang KW, Chung JK, Kim EE, Lee DS. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma. *Nucl Med Commun*. 2014 Jun;35(6):606-12.
95. Pak K, Cheon GJ, Lee KE, Park YJ, Choi HS, Min HS, Kang KW, Chung JK, Kim EE, Lee DS. Incidental thyroid cancer detected by 18F-FDG PET: does it have different clinicopathological features? *Nucl Med Commun*. 2014 May;35(5):453-8.
96. Nam HY, Paeng JC, Chung JK, Kang KW, Cheon GJ, Kim Y, Park DJ, Park YJ, Min HS, Lee DS. Monitoring differentiated thyroid cancer patients with negative serum thyroglobulin. Diagnostic implication of TSH-stimulated antithyroglobulin antibody. *Nuklearmedizin*. 2014;53(2):32-8.
97. Chung HH, Cheon GJ, Kang KW, Kim JW, Park NH, Song YS. Preoperative PET/CT FDG standardized uptake value of pelvic lymph nodes as a significant prognostic factor in patients with uterine cervical cancer. *Eur J Nucl Med Mol Imaging*. 2014 Apr;41(4):674-81.
98. Koo HR, Park JS, Kang KW, Cho N, Chang JM, Bae MS, Kim WH, Lee SH, Kim MY, Kim JY, Seo M, Moon WK. 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes. *Eur Radiol*. 2014 Mar;24(3):610-8.
99. Budiawan H, Cheon GJ, Im HJ, Lee SJ, Paeng JC, Kang KW, Chung JK, Lee DS. Heterogeneity Analysis of 18F-FDG Uptake in Differentiating Between Metastatic and Inflammatory Lymph Nodes in Adenocarcinoma of the Lung: Comparison with Other Parameters and its Application in a Clinical Setting. *Nucl Med Mol Imaging*. 2013 Dec;47(4):232-41.
100. Kim YK, Kang KW, Hong SK, Cho KH, Choi HS. Is it safe to eat fish? *J Korean Med Sci*. 2013 Dec;28(12):1701-2.
101. Kim JH, Chung HH, Jeong MS, Song MR, Kang KW, Kim JS. One-step detection of circulating tumor cells in ovarian cancer using enhanced fluorescent silica nanoparticles. *Int J Nanomedicine*. 2013;8:2247-57.
102. Koo HR, Moon WK, Chun IK, Eo JS, Jeyanth JX, Chang JM, Cho N, Kang KW. Background ¹⁸F-FDG uptake in positron emission mammography (PEM): correlation with mammographic density and background parenchymal enhancement in breast MRI. *Eur J Radiol*. 2013 Oct;82(10):1738-42.
103. Choi H, Yoo MY, Cheon GJ, Kang KW, Chung JK, Lee DS. Parametric Cerebrovascular Reserve Images Using Acetazolamide (99m)Tc-HMPAO SPECT: A Feasibility Study of Quantitative Assessment. *Nucl Med Mol Imaging*. 2013 Sep;47(3):188-95.
104. Chun IK, Cheon GJ, Paeng JC, Kang KW, Chung JK, Lee DS. Detection and Characterization of Parathyroid Adenoma/Hyperplasia for Preoperative Localization: Comparison Between (11)C-Methionine PET/CT and (99m)Tc-Sestamibi Scintigraphy. *Nucl Med Mol Imaging*. 2013 Sep;47(3):166-72.
105. Eo JS, Paeng JC, Lee S, Lee YS, Jeong JM, Kang KW, Chung JK, Lee DS. Angiogenesis imaging in myocardial infarction using 68Ga-NOTA-RGD PET: characterization and application to therapeutic efficacy monitoring in rats. *Coron Artery Dis*. 2013 Jun;24(4):303-11.
106. Kim C, Chung HH, Oh SW, Kang KW, Chung JK, Lee DS. Differential Diagnosis of Borderline Ovarian Tumors from Stage I Malignant Ovarian Tumors using FDG PET/CT. *Nucl Med Mol Imaging*. 2013 Jun;47(2):81-8.
107. Lee ES, Paeng JC, Park CM, Chang W, Lee WW, Kang KW, Chung JK, Lee DS. Metabolic Characteristics of Castleman Disease on 18F-FDG PET in Relation to Clinical Implication. *Clin Nucl Med*. 2013 May;38(5):339-42.
108. Choi H, Paeng JC, Kim DW, Lee JK, Park CM, Kang KW, Chung JK, Lee DS. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. *Lung Cancer*. 2013 Mar;79(3):242-7.
109. Quan B, Choi K, Kim YH, Kang KW, Chung DS. Near infrared dye indocyanine green doped silica nanoparticles for biological imaging. *Talanta*. 2012 Sep 15;99:387-93.
110. Kim YI, Im HJ, Paeng JC, Lee JS, Eo JS, Kim DH, Kim EE, Kang KW, Chung JK, Lee DS. Validation of Simple Quantification Methods for 18F-FP-CIT PET Using Automatic Delineation of Volumes of

- Interest Based on Statistical Probabilistic Anatomical Mapping and Isocontour Margin Setting. *Nucl Med Mol Imaging*. 2012 Dec;46(4):254-260.
111. Choi H, Paeng JC, Chun IK, Baik KD, Kang KW, Chung JK, Lee DS. A Case of Enterocutaneous Fistula Diagnosed with Tc-99m DTPA Fistulography Using Hybrid SPECT/CT. *Nucl Med Mol Imaging*. 2012 Jun;46(2):111-114.
112. Noh YW, Kong SH, Choi DY, Park HS, Yang HK, Lee HJ, Kim HC, Kang KW, Sung MH, Lim YT. Near-Infrared Emitting Polymer Nanogels for Efficient Sentinel Lymph Node Mapping. *ACS Nano*. 2012 Sep 25;6(9):7820-31.
113. Chung HH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, Kang SB. Predictive role of post-treatment [(18)F]FDG PET/CT in patients with uterine cervical cancer. *Eur J Radiol*. 2012 Aug;81(8):e817-22.
114. Jeun M, Lee S, Kang JK, Tomitaka A, Kang KW, Kim YI, Takemura Y, Chung KW, Kwak JY, Bae S. Physical Limits of Pure Superparamagnetic Fe₃O₄ Nanoparticles for a Local Hyperthermia Agent in Nanomedicine. *Applied Physics Letters*. 2012 Mar; 100(9):092406.
115. Kim JG, Kang MJ, Yoon YK, Kim HP, Park J, Song SH, Han SW, Park JW, Kang GH, Kang KW, Oh do Y, Im SA, Bang YJ, Yi EC, Kim TY. Heterodimerization of glycosylated insulin-like growth factor-1 receptors and insulin receptors in cancer cells sensitive to anti-IGF1R antibody. *PLoS One*. 2012;7(3):e33322.
116. Chung HH, Kwon HW, Kang KW, Kim JW, Park NH, Song YS, Kang SB. Preoperative [F]FDG PET/CT predicts recurrence in patients with epithelial ovarian cancer. *J Gynecol Oncol*. 2012 Jan;23(1):28-34.
117. Eguchi M, Kim YH, Kang KW, Shim CY, Jang Y, Dorval T, Kim KJ, Sweeney G. Ischemia-Reperfusion Injury Leads to Distinct Temporal Cardiac Remodeling in Normal versus Diabetic Mice. *PLoS One*. 2012;7(2):e30450.
118. Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, Park IA, Noh DY, Chung JK, Bang YJ. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy. *Breast Cancer*. 2013 Apr;20(2):167-73
119. Lee E, Park CM, Kang KW, Goo JM, Kim MA, Paeng JC, Lee HJ, Park HS, Chung DH. 18F-FDG PET/CT features of pulmonary sclerosing hemangioma. *Acta Radiol*. 2013 Feb 1;54(1):24-9
120. Choi SH, Cho HR, Kim HS, Kim YH, Kang KW, Kim H, Moon WK. Imaging and quantification of metastatic melanoma cells in lymph nodes with a ferritin MR reporter in living mice. *NMR Biomed*. 2012 May;25(5):737-45
121. Chung HH, Kwon HW, Kang KW, Park NH, Song YS, Chung JK, Kang SB, Kim JW. Prognostic Value of Preoperative Metabolic Tumor Volume and Total Lesion Glycolysis in Patients with Epithelial Ovarian Cancer. *Ann Surg Oncol*. 2012 Jun;19(6):1966-72.
122. Jun BH, Hwang DW, Jung HS, Jang J, Kim H, Kang H, Kang T, Kyeong S, Lee H, Jeong DH, Kang KW, Youn H, Lee DS, Lee YS. Ultrasensitive, Biocompatible, Quantum-Dot-Embedded Silica Nanoparticles for Bioimaging. *Adv Funct Mater*. 2012 May;22(9):1843-9.
123. Kim JS, Kim YH, Kim JH, Kang KW, Tae EL, Youn H, Kim D, Kim SK, Kwon JT, Cho MH, Lee YS, Jeong JM, Chung JK, Lee DS. Development and in vivo imaging of a PET/MRI nanoprobe with enhanced NIR fluorescence by dye encapsulation. *Nanomedicine (Lond)*. 2012 Feb;7(2):219-29.
124. Kim MY, Cho N, Chang JM, Yun BL, Bae MS, Kang KW, Moon WK. Mammography and ultrasonography evaluation of unexpected focal 18F-FDG uptakes in breast on PET/CT. *Acta Radiol*. 2012 Apr 1;53(3):249-54.
125. Kim MY, Kim OR, Choi YS, Lee H, Park K, Lee CT, Kang KW, Jeong S. Selection and characterization of tenascin C targeting peptide. *Mol Cells*. 2012 Jan;33(1):71-7
126. Kim JH, Lee JS, Kang KW, Lee HY, Han SW, Kim TY, Lee YS, Jeong JM, Lee DS. Whole-Body Distribution and Radiation Dosimetry of (68)Ga-NOTA-RGD, a Positron Emission Tomography Agent for Angiogenesis Imaging. *Cancer Biother Radiopharm*. 2012 Feb;27(1):65-71.
127. Eo JS, Chun IK, Paeng JC, Kang KW, Lee SM, Han W, Noh DY, Chung JK, Lee DS. Imaging sensitivity of dedicated positron emission mammography in relation to tumor size. *Breast*. 2012 Feb;21(1):66-71

128. Park SH, Moon WK, Cho N, Chang JM, Im SA, Park IA, Kang KW, Han W, Noh DY. Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer. *Eur Radiol.* 2012 Jan;22(1):18-25.
129. Choi SH, Kim YT, Kim SK, Kang KW, Goo JM, Kang CH, Kim JH. Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer. *Ann Thorac Surg.* 2011 Nov;92(5):1826-32.
130. Kwon HW, Paeng JC, Nahm FS, Kim SG, Zehra T, Oh SW, Lee HS, Kang KW, Chung JK, Lee MC, Lee DS. Diagnostic Performance of Three-Phase Bone Scan for Complex Regional Pain Syndrome Type 1 with Optimally Modified Image Criteria. *Nucl Med Mol Imaging.* 2011 Dec;45(4):261-267.
131. Paeng JC, Kang KW, Park DJ, Oh SW, Chung JK. Alternative Medical Treatment for Radioiodine-Refractory Thyroid Cancers. *Nucl Med Mol Imaging.* 2011 Dec;45(4):241-247.
132. Kim C, Oh SW, Bae JM, Jung KC, Kim SH, Kang KW, Lee DS. Nonfunctioning Periurethral Paraganglioma Incidentally Detected by FDG PET/CT. *Nucl Med Mol Imaging.* 2011 Jun;45(2):145-148.
133. Im HJ, Kim YI, Kim WH, Kim SH, Kang KW. Intratumoral Heterogeneous F-18 Fluorodeoxyglucose Uptake Corresponds with Glucose Transporter-1 and Ki-67 Expression in a Case of Krukenberg Tumor: Localization of Intratumoral Hypermetabolic Focus by Fused PET/MR Image. *Nucl Med Mol Imaging.* 2011 Jun;45(2):139-144.
134. Kwon HW, Lee HY, Kim SG, Kim W, Jung YJ, Kang KW, Chung JK, Lee MC, Lee DS. Quantitative Measurement of Serum Hepatitis B Surface Antigen Using an Immunoradiometric Assay in Chronic Hepatitis B. *Nucl Med Mol Imaging.* 2011 Mar;45(1):15-20.
135. Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, Park IA, Noh DY, Chung JK, Bang YJ. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. *BMC Cancer.* 2011 Oct 20;11:452.
136. Kim YH, Jeon J, Hong SH, Rhim WK, Lee YS, Youn H, Chung JK, Lee MC, Lee DS, Kang KW, Nam JM. Tumor Targeting and Imaging Using Cyclic RGD-PEGylated Gold Nanoparticle Probes with Directly Conjugated Iodine-125, Small. 2011 Jul 18;7(14):2052-60
137. Park JS, Moon WK, Lyou CY, Cho N, Kang KW, Chung JK. The assessment of breast cancer fluorodeoxyglucose positron emission tomography. *Acta Radiol.* 2011 Feb 1;52(1):21-8.
138. Chung HH, Kim JW, Han KH, Eo JS, Kang KW, Park NH, Song YS, Chung JK, Kang SB. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. *Gynecol Oncol.* 2011 Feb;120(2):270-4.
139. Lim I, Kang KW, Myung JK, Jung KC, Jeon YH, Kang JY, Kim YH, Chung JK, Lee DS. Extravasation of hydroxymethylene diphosphonate-induced subcutaneous inflammation, histologically demonstrated in BALB/c mice. *J Nucl Med.* 2010 Oct;51(10):1573-5.
140. Kim SG, Paeng JC, Eo JS, Shim HK, Kang KW, Chung JK, Lee MC, Lee DS. Behavior and Awareness of Thyroid Cancer Patients in Korea Having Non-Hospitalized Low-Dose Radioiodine Treatment with Regard to Radiation Safety. *Nucl Med Mol Imaging.* 2010 Dec;44(4):267-272.
141. Chung JK, Youn HW, Kang JH, Lee HY, Kang KW. Sodium Iodide Symporter and the Radioiodine Treatment of Thyroid Carcinoma. *Nucl Med Mol Imaging.* 2010 Apr;44(1):4-14.
142. Chung HH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, Kang SB. Post-treatment [(18)F]FDG maximum standardized uptake value as a prognostic marker of recurrence in endometrial carcinoma. *Eur J Nucl Med Mol Imaging.* 2011 Jan;38(1):74-80.
143. Kim YH, Oh SW, Lim YJ, Park CK, Lee SH, Kang KW, Jung HW, Chang KH. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI. *Clin Neurol Neurosurg.* 2010 Nov;112(9):758-65.
144. Chung HH, Kang KW, Cho JY, Kim JW, Park NH, Song YS, Kim SH, Chung JK, Kang SB. Role of magnetic resonance imaging and positron emission tomography/computed tomography in preoperative lymph node detection of uterine cervical cancer. *Am J Obstet Gynecol.* 2010 Aug;203(2):156.e1-5.
145. Chung HH, Nam BH, Kim JW, Kang KW, Park NH, Song YS, Chung JK, Kang SB. Preoperative [(18)F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancer. *Eur J Nucl Med Mol Imaging.* 2010 Aug;37(8):1467-73.
146. Lee HY, Chung JK, Lee JJ, Oh SW, Kang KW, Park DJ, Cho BY, Lee MC. Radioiodine Treatment of Differentiated Thyroid Carcinoma: The Experience at Seoul National University Hospital. *Current Medical Imaging Reviews,* 2010 Feb, 6, 2-7

147. Lee HY, Kang KW, Kim TY, Lee YS, Jeong JM, Han SW, Paeng JC, Chung JK, Lee MC, Lee DS. Angiogenesis Imaging Using 68Ga-RGD PET: Preliminary Report from Seoul National University Hospital. *Current Medical Imaging Reviews*. 2010 Feb; 6(1):56-59
148. Lee HY, Lee HJ, Kim YT, Kang CH, Jang BG, Chung DH, Goo JM, Park CM, Lee CH, Kang KW. Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer. *J Thorac Oncol*. 2010 Apr;5(4):497-503.
149. Jeon YH, Kim YH, Choi K, Piao JY, Quan B, Lee YS, Jeong JM, Chung JK, Lee DS, Lee MC, Lee J, Chung DS, Kang KW. In Vivo Imaging of Sentinel Nodes Using Fluorescent Silica Nanoparticles in Living Mice. *Mol Imaging Biol*. 2010 Apr;12(2):155-62.
150. Kang SH, Oh SJ, Lee SJ, Kang KW, Kim SK, Lee HY, Lee SJ, Kim IH, Lee WK. Comparison of two full automatic synthesis methods of 9-(4-[(18)F]fluoro-3-hydroxymethylbutyl)guanine using different chemistry modules. *Appl Radiat Isot*. 2009 Oct;67(10):1758-63.
151. Lee JW, Kang KW, Park SH, Lee SM, Paeng JC, Chung JK, Lee MC, Lee DS. (18)F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. *Eur J Nucl Med Mol Imaging*. 2009 Oct;36(10):1574-82.
152. Lee JW, Kang KW, Paeng JC, Lee SM, Jang SJ, Chung JK, Lee MC, Lee DS. Cancer screening using (18)F-FDG PET/CT in Korean asymptomatic volunteers: a preliminary report. *Ann Nucl Med*. 2009 Sep;23(7):685-91.
153. Lee DH, Kim SK, Lee HY, Lee SY, Park SH, Kim HY, Kang KW, Han JY, Kim HT, Lee JS. Early Prediction of Response to First-Line Therapy Using Integrated 18F-FDG PET/CT for Patients with Advanced/Metastatic Non-small Cell Lung Cancer. *J Thorac Oncol*. 2009 Jul;4(7):816-21.
154. Park EA, Lee HJ, Kim YT, Kang CH, Kang KW, Jeon YK, Goo JM, Lee CH, Park CM. EGFR gene copy number in adenocarcinoma of the lung by FISH analysis: Investigation of significantly related factors on CT, FDG-PET, and histopathology. *Lung Cancer*. 2009 May;64(2):179-86.
155. Lee JW, Paeng JC, Kang KW, Kwon HW, Suh KS, Chung JK, Lee MC, Lee DS. Prediction of Tumor Recurrence by 18F-FDG PET in Liver Transplantation for Hepatocellular Carcinoma. *J Nucl Med*. 2009 May;50(5):682-687.
156. Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, Lee WJ, Kim CM, Nam BH. A Prospective Evaluation of 18F-FDG and 11C-Acetate PET/CT for Detection of Primary and Metastatic Hepatocellular Carcinoma. *J Nucl Med*. 2008 Dec;49(12):1912-21.
157. Kang SH, Kang KW, Kim KH, Kwon B, Kim SK, Lee HY, Kong SY, Lee ES, Jang SG, Yoo BC. Upregulated HSP27 in human breast cancer cells reduces Herceptin susceptibility by increasing Her2 protein stability. *BMC Cancer*. 2008 Oct 4;8:286.
158. Tseng JR, Kang KW, Dandekar M, Yaghoubi S, Lee JH, Christensen JG, Muir S, Vincent PW, Michaud NR, Gambhir SS. Preclinical Efficacy of the c-Met Inhibitor CE-355621 in a U87 MG Mouse Xenograft Model Evaluated by 18F-FDG Small-Animal PET. *J Nucl Med*. 2008 Jan;49(1):129-134.
159. Lee S, Kim EY, Kang SH, Kim SW, Kim SK, Kang KW, Kwon Y, Shin KH, Kang HS, Ro J, Lee ES. Sentinel node identification rate, but not accuracy, is significantly decreased after pre-operative chemotherapy in axillary node-positive breast cancer patients. *Breast Cancer Res Treat*. 2007;102(3):283-8.
160. Chung HH, Kim SK, Kim TH, Lee S, Kang KW, Kim JY, Park SY. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: From diagnosis to prognosis. *Gynecol Oncol*. 2006;103(1):165-70.
161. Kim SK, Kang KW, Lee JS, Kim HK, Chang HJ, Choi JY, Lee JH, Ryu KW, Kim YW, Bae JM. Assessment of lymph node metastases using (18)F-FDG PET in patients with advanced gastric cancer. *Eur J Nucl Med Mol Imaging*. 2006;33(2):148-55.
162. Choi HJ, Roh JW, Seo SS, Lee S, Kim JY, Kim SK, Kang KW, Lee JS, Jeong JY, Park SY. Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma. *Cancer*. 2006;106(4):914-22.
163. Kim TJ, Lee KW, Kim HY, Lee JH, Kim EA, Kim SK, Kang KW. Simple Pulmonary Eosinophilia Evaluated by Means of FDG PET: the Findings of 14 Cases. *Korean J Radiol*. 2005;6:208-13.

164. Roh JW, Seo SS, Lee S, Kang KW, Kim SK, Sim JS, Kim JY, Hong EK, Cho DS, Lee JS, Park SY. Role of positron emission tomography in pretreatment lymph node staging of uterine cervical cancer: A prospective surgicopathologic correlation study. *Eur J Cancer*. 2005 Sep;41(14):2086-92.
165. Kang KW, Min JJ, Chen X, Gambhir SS. Comparison of [(14)C]FMAU, [(3)H]FEAU, [(14)C]FIAU, and [(3)H]PCV for Monitoring Reporter Gene Expression of Wild Type and Mutant Herpes Simplex Virus Type 1 Thymidine Kinase in Cell Culture. *Mol Imaging Biol*. 2005;7:296-303.
166. Lee HS, Kim MS, Lee JM, Kim SK, Kang KW, Zo JI. Intrathoracic gastric emptying of solid food after esophagectomy for esophageal cancer. *Ann Thorac Surg*. 2005 Aug;80(2):443-7.
167. Lee JS, Lee DS, Kim J, Kim YK, Kang E, Kang H, Kang KW, Lee JM, Kim JJ, Park HJ, Kwon JS, Kim SI, Yoo TW, Chang KH, Lee MC. Development of Korean standard brain templates. *J Korean Med Sci*. 2005 Jun;20(3):483-8.
168. Kim SK, Kang KW, Roh JW, Sim JS, Lee ES, Park SY. Incidental ovarian(18)F-FDG accumulation on PET: correlation with the menstrual cycle. *Eur J Nucl Med Mol Imaging*. 2005 Jul;32(7):757-63.
169. Lee DS, Lee SK, Kim YK, Lee JS, Cheon GJ, Kang KW, Kim ES, Chung JK, Lee MC. Superiority of HMPAO ictal SPECT to ECD ictal SPECT in localizing the epileptogenic zone *Epilepsia* 2002;43:263-9.
170. Kim SK, Lee DS, Lee SK, Kim YK, Kang KW, Chung CK, Chung JK, Lee MC. Diagnostic performance of [18F]FDG-PET and ictal [99mTc]-HMPAO SPECT in occipital lobe epilepsy *Epilepsia* 2001;42:1531-40
171. Lee DS, Lee JS, Kang KW, Jang MJ, Lee SK, Chung JK, Lee MC. Disparity of perfusion and glucose metabolism of epileptogenic zones in temporal lobe epilepsy demonstrated by SPM/SPAM analysis on 15O water PET, [18F]FDG-PET, and [99mTc]-HMPAO SPECT *Epilepsia* 2001;42:1515-22
172. Kang KW, Lee DS, Cho JH, Lee JS, Yeo JS, Lee SK, Chung J-K, Lee MC. Quantification of F-18 FDG PET Images in Temporal Lobe Epilepsy Patients Using Probabilistic Brain Atlas *NeuroImage* 2001;14:1-6
173. Lee DS, Lee SK, Kim SK, Kang KW, Lee KH, Hyun IY, Chung J-K, Lee MC. Late postictal residual perfusion abnormality in epileptogenic zone found on 6-h postictal SPECT *Neurology* 2000;55:835-41

Book Chapters and Books

1. Kang KW, Lee JS, Lee DS, Lee MC. Chapter 22: Partial Volume Correction of Simulated PET and 18F FDG PET from 14 Normal Brains In: Senda M, Kimura Y, Herscovitch P, eds. *Brain Imaging Using PET*. San Diego: Academic Press, 2002 pp153-7.
2. Kang KW, Jeong JM, Beer AJ. Chapter 12: Angiogenesis PET Using Radiolabeled RGD Peptides In: Fanti S, Farsad M, Mansi L, eds. *PET-CT Beyond FDG*. Berlin: Springer, 2010 pp195-211.
3. Keon Wook Kang. Chapter 17: In Vivo Molecular Imaging. In: E Edmund Kim, Dong-Soo Lee, Ukihide Tateishi, Richard P Baum, eds. *Handbook of Nuclear Medicine and Molecular Imaging*. Singapore: World Scientific, 2012 pp381-93.
4. Lee HY, Chung JK, Oh SW, Lee JJ, Kang KW, Park DJ, Cho BY, Lee MC. Chapter 19: Direct Visualization of Therapeutic Radionuclide Distribution Using Nuclear Medicine Imaging: I-131 in Metastatic Thyroid Carcinoma. In: Chung Li, Mei Tian eds. *Drug Delivery Applications of Noninvasive Imaging*. Hoboken: John Wiley & Sons, Inc., 2014 pp426-31.
5. E. Edmund Kim, Hyung-Jun Lim, Dong Soo Lee, Keon Wook Kang, eds. *Atlas and Anatomy of PET/MRI, PET/CT and SPECT/CT*. Springer, 2016.
6. Kim SH, Kim SH, Park BK, Kang KW, Moon KC, Kwak C, Lee YJ, Kim JH. Chapter 1: Renal Tumors. In: Seung Hyup Kim, Jeong Yeon Cho, eds. *Oncologic Imaging: Urology*. Springer, 2017 pp1-58.
7. Keon Wook Kang. Chapter 9: PET and other functional imaging. In: Sun-Whe Kim, Hiroki Yamaue, eds. *Pancreatic Cancer*. Springer, 2017 pp123-9.
8. Keon Wook Kang, Myung Geun Song. Chapter 5: Organic Nanomaterials: Radioliposome, Albumin, Dendrimer, Polymeric Nanoparticles. In: Dong Soo Lee, eds. *Radionanomedicine: Combined Nuclear and Nanomedicine*. Springer, 2018 pp105-23.